SEC Comment Letter 0000000000-23-010686 to Regen BioPharma Inc (RGBP)
Regen BioPharma Inc
Date: Sept. 27, 2023 · CIK: 0001589150 · Accession: 0000000000-23-010686
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-274675
Letter
United States securities and exchange commission logo September 27, 2023 David Koos Chief Executive Officer Regen BioPharma Inc. 4700 Spring Street, Suite 304 La Mesa, CA 91942 Re:Regen BioPharma Inc. Registration Statement on Form S-1 Filed September 25, 2023 File No. 333-274675 Dear David Koos: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dillon Hagius at 202-551-7967 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
September 27, 2023
David Koos
Chief Executive Officer
Regen BioPharma Inc.
4700 Spring Street, Suite 304
La Mesa, CA 91942
Re:Regen BioPharma Inc.
Registration Statement on Form S-1
Filed September 25, 2023
File No. 333-274675
Dear David Koos:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Dillon Hagius at 202-551-7967 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences